Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of LY3502970 in Healthy Participants
NCT06085482Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orforglipron in obesity and type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Absolute Bioavailability of LY3502970. Started Oct 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06085482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085482.